Healthcare [ 12/13 ] | Drug Manufacturers - Specialty & Generic [ 83/159 ]
NASDAQ | Common Stock
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada.
It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.
The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer.
It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products.
In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications.
Sunshine Biopharma, Inc. is headquartered in New York, New York.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 24 | -0.05 Increased by +95.02% | -8.00 Increased by +99.35% |
| Mar 28, 24 | -5.00 Increased by +95.20% | -3.00 Decreased by -66.67% |
| Nov 13, 23 | -0.04 Increased by +50.00% | -0.06 Increased by +33.33% |
| Aug 14, 23 | -0.02 Increased by +33.33% | -0.08 Increased by +75.00% |
| May 11, 23 | -1.05 Decreased by -356.52% | - |
| Dec 31, 22 | -104.10 Decreased by -40.14 K% | - |
| Nov 7, 22 | -0.08 Decreased by -700.00% | - |
| Aug 4, 22 | -0.03 Decreased by -200.00% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 7.68 M Increased by +94.94% | -1.25 M Increased by +94.68% | Decreased by -16.28% Increased by +97.27% |
| Sep 30, 23 | 5.96 M Increased by +4.39 K% | -651.48 K Increased by +55.29% | Decreased by -10.94% Increased by +99.00% |
| Jun 30, 23 | 5.56 M Increased by +3.60 K% | -902.11 K Decreased by -136.19% | Decreased by -16.22% Increased by +93.62% |
| Mar 31, 23 | 4.89 M Increased by +3.89 K% | -1.70 M Decreased by -37.71% | Decreased by -34.79% Increased by +96.55% |
| Dec 31, 22 | 3.94 M Increased by +4.53 K% | -23.51 M Decreased by -3.62 K% | Decreased by -596.78% Decreased by -176.14% |
| Sep 30, 22 | 132.81 K Increased by +163.63% | -1.46 M Increased by +63.93% | Decreased by -1.10 K% Increased by +86.32% |
| Jun 30, 22 | 150.31 K Increased by +184.27% | -381.95 K Increased by +86.73% | Decreased by -254.11% Increased by +95.33% |
| Mar 31, 22 | 122.64 K Increased by +206.17% | -1.24 M Increased by +80.01% | Decreased by -1.01 K% Increased by +93.47% |